临床误诊误治

参考文献

[1]Hsieh J J,Purdue M P,Signoretti S,et al.Renal cell carcinoma[J].Nat Rev Dis Primers,2017,3:17009.

[2]Moch H,Cubilla A L,Humphrey P A,et al.The 2016WHO classification of tumours of the urinary system and male genital organs-part a:renal,penile,and testicular tumours[J].Eur Urol,2016,70(1):93-105.

[3]Schwaab T,Schwarzer A,Wolf B,et al.Clinical and immunologic effects of intranodal autologous tumor lysatedendritic cell vaccine with aldesleukin(interleukin 2)and ifn-(alpha)2a therapy in metastatic renal cell carcinoma patients[J].Clin Cancer Res,2009,15(15):4986-4992.

[4]De Meerleer G,Khoo V,Escudier B,et al.Radiotherapy for renal-cell carcinoma[J].Lancet Oncol,2014,15(4):170-177.

[5]Maroto J P,del Muro X G,Mellado B,et al.Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma(RCC)[J].Clin Transl Oncol,2013,15(9):698-704.

[6]Okon K.Pathology of renal tumors in adults.Molecular biology,histopathological diagnosis and prognosis[J].Pol J Pathol,2008,59(3):129-176.

[7]Atzpodien J,Buer J,Sel S,et al.Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma[J].Urologe A,1999,38(5):474-478.

[8]Massari F,Santoni M,Ciccarese C,et al.The immunocheckpoints in modern oncology:the next 15 years[J].Expert Opin Biol Ther,2015,15(7):917-921.

[9]Buti S,Rovere R K,Donini M,et al.Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-alpha in 146 patients with renal cell carcinoma[J].Tumori,2012,98(1):45-52.

[10]Brahms A,Mudhasani R,Pinkham C,et al.Sorafenib impedes rift valley fever virus egress by inhibiting valosincontaining protein function in the cellular secretory pathway[J].J Virol,2017,91(21):e00968-17.

[11]Randrup Hansen C,Grimm D,Bauer J,et al.Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma[J].Int J Mol Sci,2017,18(2).

[12]Takyar S,Diaz J,Sehgal M,et al.First-line First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma:a systematic review of published randomized controlled trials[J].Anticancer Drugs,2016,27(5):383-397.

[13]Motzer R J,Hutson T E,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J].N Engl J Med,2007,356(2):115-124.

[14]Reiter M A,Kurosch M,Haferkamp A.Renal cell carcinoma:Drug therapy and prognostic models[J].Urologe A,2015,54(5):735-746.

[15]Motzer R J,Hutson T E,Cella D,et al.Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J].N Engl J Med,2013,369(8):722-731.

[16]Kumar R,Kapoor A.Current management of metastatic renal cell carcinoma:evolving new therapies[J].Curr Opin Support Palliat Care,2017,11(3):231-237.

[17]Calvo E,Schmidinger M,Heng D Y,et al.Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy[J].Cancer Treat Rev,2016,50:109-117.

[18]Fischer S,Gillessen S,Rothermundt C.Sequence of treatment in locally advanced and metastatic renal cell carcinoma[J].Transl Androl Urol,2015,4(3):310-325.

[19]Frampton J E.Pazopanib:a review in advanced renal cell carcinoma[J].Target Oncol,2017,12(4):543-554.

[20]Rodriguez Vida A,Hutson T E,Bellmunt J,et al.New treatment options for metastatic renal cell carcinoma[J].ESMO Open,2017,2(2):000185.

[21]Zarrabi K,Fang C,Wu S.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy[J].J Hematol Oncol,2017,10(1):38.

[22]Abdelaziz A,Vaishampayan U.Cabozantinib for renal cell carcinoma:current and future paradigms[J].Curr Treat Options Oncol,2017,18(3):18.

[23]Neuwelt A J,Mathur S,Johnson A T,et al.Cabozantinib use in renal cell carcinoma[J].Drugs Today(Barc),2017,53(5):299-307.

[24]Dorff T B,Longmate J A,Pal S K,et al.Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer[J].Cancer,2017,23(23):4566-4573.

[25]Porta C,Chiellino S,Ferrari A,et al.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma[J].Expert Opin Pharmacother,2017,18(2):205-216.

[26]Bedke J,Gauler T,Grunwald V,et al.Systemic therapy in metastatic renal cell carcinoma[J].World J Urol,2017,35(2):179-188.

[27]Stanculeanu D L,Lazescu A,Zob D D,et al.Metastatic clear cell renal carcinoma-an unusual response to Temsirolimus in second line therapy[J].J Med Life,2016,9(2):193-198.

[28]Buczek M,Escudier B,Bartnik E,et al.Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma:from the patient's bed to molecular mechanisms[J].Biochim Biophys Acta,2014,1845(1):31-41.

[29]Sosman J,Puzanov I.Combination targeted therapy in advanced renal cell carcinoma[J].Cancer,2009,115(10Suppl):2368-2375.

[30]Flaherty K T,Manola J B,Pins M,et al.BEST:a randomized phase ii study of vascular endothelial growth factor,raf kinase,and mammalian target of rapamycin combination targeted therapy with bevacizumab,sorafenib,and temsirolimus in advanced renal cell carcinoma--a trial of the ecog-acrin cancer research group(e2804)[J].J Clin Oncol,2015,33(21):2384-1391.

[31]Eto M.New treatment options for renal cell carcinoma-efficacy and safety of immune checkpoint inhibitors[J].Gan To Kagaku Ryoho,2017,44(8):667-673.

[32]Guo L,Zhang H,Chen B.Nivolumab as programmed death-1(PD-1)inhibitor for targeted immunotherapy in tumor[J].J Cancer,2017,8(3):410-416.

[33]Mazza C,Escudier B,Albiges L.Nivolumab in renal cell carcinoma:latest evidence and clinical potential[J].Ther Adv Med Oncol,2017,9(3):171-181.

[34]Motzer R J,Rini B I,Mc Dermott D F,et al.Nivolumab for metastatic renal cell carcinoma:results of a randomized phase ii trial[J].J Clin Oncol,2015,33(13):1430-1437.